Q1 2022 Results

Company overview CRM Financial performance Immunology AdakveoⓇ Financial review Neuroscience 2022 priorities Appendix References Innovation: Pipeline overview Innovation: Clinical trials Abbreviations Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health - P-selectin inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) NCT03474965 SOLACE-Kids (CSEG101B2201) Prevention of VOC in pediatric patients with SCD Phase 2 100 PK/PD and safety of SEG101 at 5 mg/kg SEG101 (crizanlizumab) at a dose of 5 mg/kg by IV infusion ± Hydroxyurea/Hydroxycarbamide Pediatric SCD patients with VOC H2-2021 (pediatric patients >=12 year old) 2024 (pediatric patients <12 year old) Publication TBD 103 Investor Relations | Q1 2022 Results 1 NOVARTIS | Reimagining Medicine

View entire presentation